Association between SGLT2 inhibitor use and the risk of vertebral augmentation after initial osteoporotic vertebral fracture in patients with type 2 diabetes
Authors' conclusion
In patients with T2DM and osteoporosis, SGLT2 inhibitor use was associated with an increased likelihood of vertebral augmentation following an initial osteoporotic vertebral fracture, suggesting potential differences in post-fracture clinical course or management intensity.
Study context
- Population
- Adults with T2DM, osteoporosis and a first documented osteoporotic vertebral compression fracture (VCF); prior vertebral augmentation, vertebral malignancy or inflammatory spondylopathies excluded1,757 per cohort after matching
- Participants
- 1,757 vs 1,757
- Exposure
- SGLT2 inhibitor use within 6 months before fracture vs non-use
- SGLT2 inhibitor usersn = 1,757
- Non-usersn = 1,757reference
- Outcome
- Vertebral augmentation
- Follow-up
- Within 6 months after the index fracture
Methodological detailspropensity-score matched (1:1), TriNetX Global Collaborative Network
- Propensity-score matched (1:1)
- TriNetX Global Collaborative Network
Main finding
As reported in the abstract
within 6 months after the initial VCF
Observational data: associations, not effects.
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Association between SGLT2 inhibitor use and the risk of vertebral augmentation after initial osteoporotic vertebral fracture in patients with type 2 diabetes. Osteoporos Int. Published 8 January 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →